Cargando…
USE OF TOCILIZUMAB AND MESENCHYMAL STROMAL CELLS IN THE TREATMENT OF SEVERE COVID-19 - A CASE REPORT
BACKGROUND: Currently, there is no specific treatment for coronavirus disease, and some drugs and cell-based therapy have been tested as alternatives. This work aims to evaluate the effects of the combined use of humanized recombinant monoclonal antibody capable of binding the IL-6 receptor (Tociliz...
Autores principales: | Senegaglia, AC, Rebelatto, CLK, Franck, CL, Lima, JS, Daga, DR, Shigunov, P, Azambuja, AP, Bana, EG, Marsaro, DB, Schaidt, B, Micosky, A, Jamur, VR, Vaz, IM, Schluga, Y, Leite, LMB, Ribeiro, LL, Correa, A, Brofman, PRS |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079859/ http://dx.doi.org/10.1016/j.jcyt.2021.02.111 |
Ejemplares similares
-
USO COMBINADO DE TOCILIZUMABE E CÉLULAS-TRONCO MESENQUIMAIS NO TRATAMENTO DA COVID-19 – RELATO DE CASO
por: Senegaglia, A.C., et al.
Publicado: (2020) -
Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report
por: Senegaglia, Alexandra Cristina, et al.
Publicado: (2021) -
Broad Decline in Viral Infections During COVID-19 Lockdown: Association with Lung Function in Lung Transplant Recipients
por: de Zwart, A.E., et al.
Publicado: (2022) -
Differences In Lung Fluid Quality Between Decompensated Heart Failure Patients And Covid-19 Patients- Results Of The Impedance-corona Trial
por: Shochat, Michael Kleiner, et al.
Publicado: (2023) -
Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial
por: Rebelatto, Carmen Lúcia Kuniyoshi, et al.
Publicado: (2022)